scholarly journals Toxicity of cytarabine constant rate infusion in dogs with high‐grade non‐Hodgkin lymphoma with bone marrow or central nervous system involvement

2019 ◽  
Vol 98 (3) ◽  
pp. 69-78
Author(s):  
A Guillen ◽  
R Finotello ◽  
P Wynne ◽  
A Harper ◽  
D Killick ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Bone Marrow ◽  
Nervous System ◽  
Hodgkin Lymphoma ◽  
Central Nervous System Involvement ◽  
High Grade ◽  
Constant Rate Infusion ◽  
Non Hodgkin Lymphoma ◽  
Constant Rate ◽  
Rate Infusion

scholarly journals P03.01 Secondary central nervous system lymphoma (SCNSL) in patient with non Hodgkin lymphoma (NHL): a case report

2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii24-iii24
Author(s):  
E Susanti ◽  
N Suci Rahayu ◽  
M Fuad
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Case Report ◽  
Ct Scan ◽  
Hodgkin Lymphoma ◽  
Central Nervous System Involvement ◽  
Central Nervous System Lymphoma ◽  
Head Ct ◽  
System Involvement ◽  
Non Hodgkin Lymphoma

Abstract BACKGROUND non Hodgkin lymphoma (NHL) is a systemic cancer that originates from lymphocites. Central nervous system lymphoma is a rare form of non Hodgkin lymphoma that involve brain parenchym and spinal cord. The most common type of nervous system involvement is a leptomeningeal metastases. Whereas brain metastases is an extremely rare finding in NHL. We present a case report of NHL patient which metastasized to brain parenchym. MATERIAL AND METHODS Case report: a fourty two year old male patient suffered from seizure in September 2018, 7 days prior to hospitalized. severe headache and weakness on the left extremities were found in addition to seizure. A single nodule on the right frontal and another nodules on the right neck region were also found since 7 months ago. Patient was diagnosed with NHL in 2017 after a confirmed biopsy of NHL and underwent a chemotherapy procedure, but uncompleted. After head ct scan procedure in September 2018, which depicted a round mass in frontal lobe, patient underwent a complete chemotherapy procedure with CHOP regimen in September 2018. Another head ct scan was performed in January 2019 after a completed chemotherapy cycle which showed significant decrease in tumour size. RESULTS before and after head ct scan showed significant decrease in tumour size, from 4cmx2cm before chemotherapy and 2.5cmx1.3cm after chemotherapy CONCLUSION central nervous system involvement in NHL is a rare condition that carries a poor prognosis. Prophylaxis therapy still on debate about it’s efficacy to prevent this disease from spreading or relapse. Awareness of the possibility central nervous system involvement should always remain in a physician’s mind when dealing with NHL patients.

Use of F-18 FDG PET/CT in Non-Hodgkin Lymphoma With Central Nervous System Involvement

2011 ◽  
Vol 36 (6) ◽  
pp. e45-e49 ◽  
Author(s):  
Sébastien Cimarelli ◽  
Catherine Sebban ◽  
Philippe Thiesse ◽  
Marie Pierre Sunyach ◽  
Jean-Yves Blay ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Hodgkin Lymphoma ◽  
Fdg Pet ◽  
Central Nervous System Involvement ◽  
System Involvement ◽  
Non Hodgkin Lymphoma ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals RARE-29. PRIMARY CENTRAL NERVOUS SYSTEM NON-HODGKIN LYMPHOMA IN AN 11-YEAR-OLD BOY: A CASE REPORT

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii448-iii448
Author(s):  
Jorge Luis Ramírez-Melo ◽  
Regina M Navarro-Martin del Campo ◽  
Manuel D Martinez-Albarran ◽  
Fernando Sánchez-Zubieta ◽  
Ana L Orozco-Alvarado ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Hodgkin Lymphoma ◽  
Central Nervous System Lymphoma ◽  
Complete Response ◽  
High Dose ◽  
Illustrative Case ◽  
Tumor Biopsy ◽  
Non Hodgkin Lymphoma ◽  
The Right

Abstract BACKGROUND Primary central nervous system lymphoma (PCNSL) are very rare in children. CLINICAL CASE: An 11-year-old male presented with a 2 months history with myoclonic movements in the upper right limb, and a sudden frontal headache, gait disturbance due to right hemiparesis and an ipsilateral convulsive episode. Upon admission he had critical condition, with hypertensive skull syndrome, Glasgow of 12, Karnofsky 40%, right hemiparesis, swallowing disorder, facial paralysis, and loss of photo motor reflex and unilateral amaurosis. A CT and MRI showed a huge tumor mass in the left tempo-parietal region, infiltrating the white matter and shifting the midline. A Tumor biopsy was done, and reported diffuse small cell non-Hodgkin lymphoma of high-grade, Burkitt type. Systemic lymphoma workup was negative. He received six cycles of chemotherapy based on high dose methotrexate, rituximab and triple intrathecal.After the second cycle an ophthalmologic evaluation was done, and found infiltration to the right retina, for which 6 cycles of intra vitreous chemotherapy with methotrexate were applied, he showed an excellent response, and recovered all his neurological functions except that right hemianopia persist. Control MRI showed partial response at 2nd cycle and complete response after the 4th cycle. No Radiation was performed. CONCLUSION This report highlights the fact that pediatric PCNSL may be effectively treated by a combination of HDMTX and rituximab-based chemoimmunotherapy without irradiation. Lack of awareness of this rare entity may lead to extense resections of brain, and potential permanent secuelae that were avoided in this illustrative case.

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment

Blood ◽  
2003 ◽  
Vol 101 (2) ◽  
pp. 466-468 ◽  
Author(s):  
James L. Rubenstein ◽  
Dan Combs ◽  
Jay Rosenberg ◽  
Arthur Levy ◽  
Michael McDermott ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Hodgkin Lymphoma ◽  
Phase 1 ◽  
Central Nervous System Lymphoma ◽  
Serum Levels ◽  
Pharmacokinetic Analysis ◽  
Lymphomatous Meningitis ◽  
Cell Surface Molecule ◽  
Non Hodgkin Lymphoma

Most lymphomas that involve the central nervous system are B-cell neoplasms that express the cell surface molecule CD20. After intravenous administration, rituximab can be reproducibly measured in the cerebrospinal fluid (CSF) in patients with primary central nervous system lymphoma; however, the CSF levels of rituximab are approximately 0.1% of serum levels associated with therapeutic activity in patients with systemic non-Hodgkin lymphoma. Because lymphomatous meningitis is a frequent complication of non-Hodgkin lymphoma, we have conducted an analysis of the safety and pharmacokinetics of direct intrathecal administration of rituximab using cynomolgus monkeys. No significant acute or delayed toxicity, neurologic or otherwise, was detected. Pharmacokinetic analysis suggests that drug clearance from the CSF is biphasic, with a terminal half-life of 4.96 hours. A phase 1 study to investigate the safety and pharmacokinetics of intrathecal rituximab in patients with recurrent lymphomatous meningitis will be implemented based on these findings.

Sign in / Sign up

Export Citation Format

Share Document